Sertaconazole nitrate

Synonyms: 硝酸舍他康唑; FI7056
Sertaconazole nitrate (FI7056) 是一种局部广谱抗真菌剂,可通过激活 p38-COX-2-PGE 2 通路发挥抗炎活性,同时也是一种微管蛋白抑制剂,具有抗癌细胞增殖活性,可诱导细胞凋亡和自噬并抑制细胞迁移,因而具有较好的抗癌活性。
产品编号: MS-W78721 纯度: 99.19% CAS No.: 99592-39-9 分子式: C20H16Cl3N3O4S 分子量: 500.78
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Sertaconazole nitrate (FI7056) 是一种局部广谱抗真菌剂,可通过激活 p38-COX-2-PGE 2 通路发挥抗炎活性,同时也是一种微管蛋白抑制剂,具有抗癌细胞增殖活性,可诱导细胞凋亡和自噬并抑制细胞迁移,因而具有较好的抗癌活性。

生物实验数据

生物活性 Sertaconazole nitrate (FI7056) is a topical broad-spectrum antifungal agent that exerts anti-inflammatory activity by activating the p38-COX-2-PGE 2 pathway, and it is also a tubulin inhibitor with anti-cancer cell proliferation activity that induces apoptosis and autophagy and inhibits cell migration, thereby exhibiting promising anticancer activity.
IC50 & Target Proliferation (human lymphocytes):4 μg/mL
体外研究
(In Vitro)

Sertaconazole nitrate (0.03-40 μg/mL;24 h) 抑制 150 株酵母菌,其中包括六种念珠菌,平均 MIC 为 0.77 μg/mL。
Sertaconazole nitrate (1 μg/mL;5、10、30、60 分钟) 以时间依赖性方式激活 p38 MAP 激酶。
Sertaconazole nitrate (1,2 μg/mL;6、8 或 24 小时) 通过角质形成细胞中的 COX-2 增加 PGE2 的两倍释放,这取决于 p38 激活。
Sertaconazole nitrate (10,20,30,40 μM;24 h) 通过解聚间期和纺锤体微管诱导强烈的有丝分裂停滞,从而诱导染色体聚集缺陷并产生抗增殖作用。
Sertaconazole nitrate (20,40 μM;24 h) 通过 p53 通路诱导 HeLa 细胞凋亡。
Sertaconazole nitrate (20,30 μM;24,48,and 72 h) 以浓度依赖性方式抑制 HeLa 细胞的迁移。
Sertaconazole nitrate (15,30 μM;24 h) 在 A549、H460 细胞中诱导自噬。

Cell Viability Assay

Cell Line: C. albicans, C. guilliermondii, C. krusei, C. parapsilosi, C. tropicalis, C. glabrata
Concentration: 0.03-40 µg/mL
Incubation Time: 24 h
Result: Againsted 150 strains of yeasts (six Candida species) which included C. albicans, C. guilliermondii, C. krusei, C. parapsilosi, C. tropicalis, C. glabrata species with arithmetic mean MIC values of 1.02, 0.51, 0.38, 0.31, 1.67 and 0.78 µg/mL, respectively.

Western Blot Analysis

Cell Line: HaCaT cells
Concentration: 1 µg/mL
Incubation Time: 5, 10, 30, 60 min
Result: Showed activity of activating p38 MAP kinase and Hsp27 in a time-dependent manner.

Western Blot Analysis

Cell Line: HaCaT cells
Concentration: 1, 2 µg/mL
Incubation Time: 6 or 8 h
Result: Induced 50% expression of COX-2 and resulted in a twofold increased in PGE2 release.

Western Blot Analysis

Cell Line: siRNA-transfected HaCaT cells (without p38 MAP kinase expression)
Concentration: 1 µg/mL
Incubation Time: 24 h
Result: Mediated induction of PGE2 was dependent on p38 activation.

Cell Proliferation Assay

Cell Line: HeLa, HEK-293, MCF-7, A549 cells
Concentration: 0-100 µM
Incubation Time: 24 h
Result: Showed antiproliferation activity with IC50s of 38, 45.1, 41.5, and 40.8 μM for HeLa, HEK-293, A549, and MCF-7 cells, respectively.
Exhibited mitotic block activity and induced cell death at concentration above 30 μM, but no significant increased in the number of mitotic cells.
Depolymerized interphase and spindle microtubules inducing defect in chromosomal congression.

Apoptosis Analysis

Cell Line: HeLa cells
Concentration: 10, 20, 40 µM
Incubation Time: 24 h
Result: Induced approximately 5%, 10%, and 21% cells apoptotic at concentrations of 10, 20 and 40 μM, respectively.

Western Blot Analysis

Cell Line: A549 cells
Concentration: 20, 40 µM
Incubation Time: 24 h
Result: Induced apoptosis through p53 pathway that the expression of p53 from 30% to 50% and 95% and p21 from 11 to 39% and 40% respectively.
Resulted in Noxa and Puma, two direct transcriptional targets of p53 to be overexpressed.

Cell Migration Assay

Cell Line: HeLa cells
Concentration: 20, 30 µM
Incubation Time: 24, 48, and 72 h
Result: Inhibited the migration of HeLa cells at concentrations lesser than its IC50, which in a concentration-dependent manner.

Cell Autophagy Assay

Cell Line: A549, H460 cells
Concentration: 15, 30 µM
Incubation Time: 24 h
Result: Increased endogenous LC3 puncta and LC3 intensity, which indicated induction of autophagy in A549 and H460 cells.
体内研究
(In Vivo)

Sertaconazole nitrate (1% (w/v);左耳涂抹一次) 抑制 TPA 诱导的 CD-1 小鼠耳水肿。

Animal Model: CD-1 mice (TPA-induced ear edema model).
Dosage: 1% (w/v)
Administration: Apply to the left ear, once.
Result: Exhibited a significant reduction of inflammation in mice by mediating PGE2 release.
性状 固体
颜色 White to off-white

化学信息

分子量 500.78
分子式 C20H16Cl3N3O4S
CAS No. 99592-39-9
别名 硝酸舍他康唑; FI7056

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.59 mM), Sonication is recommended.
10% DMSO+90% Saline: 3.33 mg/mL (6.65 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (199.69 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.9969 mL9.9844 mL19.9688 mL49.9221 mL
5 mM0.3994 mL1.9969 mL3.9938 mL9.9844 mL
10 mM0.1997 mL0.9984 mL1.9969 mL4.9922 mL
15 mM0.1331 mL0.6656 mL1.3313 mL3.3281 mL
20 mM0.0998 mL0.4992 mL0.9984 mL2.4961 mL
25 mM0.0799 mL0.3994 mL0.7988 mL1.9969 mL
30 mM0.0666 mL0.3328 mL0.6656 mL1.6641 mL
40 mM0.0499 mL0.2496 mL0.4992 mL1.2481 mL
50 mM0.0399 mL0.1997 mL0.3994 mL0.9984 mL
60 mM0.0333 mL0.1664 mL0.3328 mL0.8320 mL
80 mM0.0250 mL0.1248 mL0.2496 mL0.6240 mL
100 mM0.0200 mL0.0998 mL0.1997 mL0.4992 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础